SCHOTT Pharma AG & Co. KGaA (SHTPY) Q4 2025 Earnings Call December 11, 2025 5:00 AM EST

Company Participants

Tobias Erfurth - Head of Investor Relations Andreas Reisse - Chairperson of Management Board & CEO of SCHOTT Pharma Management AG Reinhard Mayer - Chief Financial Officer

Conference Call Participants

Giang Nguyen - Citigroup Inc., Research Division Odysseas Manesiotis - BNP Paribas, Research Division Fynn Scherzler - Deutsche Bank AG, Research Division Olivier Calvet - UBS Investment Bank, Research Division Charles Weston - RBC Capital Markets, Research Division Christian Ehmann - Joh. Berenberg, Gossler & Co. KG, Research Division Pallav Mittal - Barclays Bank PLC, Research Division Edward Hall - Stifel, Nicolaus & Company, Incorporated, Research Division

Presentation

Operator

Good morning, ladies and gentlemen, and welcome to the SCHOTT Pharma Conference regarding the results of the fiscal year 2025. [Operator Instructions] Let me now turn the floor over to Tobias Erfurth, Head of Investor Relations.

Tobias Erfurth Head of Investor Relations

Thank you very much, Beatrice. Good morning, ladies and gentlemen. Thank you for joining our earnings call for the fiscal year 2025. My name is Tobias Erfurth, and I’m Head of Investor Relations. It’s my pleasure to guide you through today’s call. With me in the room are our CEO, Andreas Reisse; and our CFO, Reinhard Mayer.

Andreas will kick off by sharing the key business and financial highlights of SCHOTT Pharma in the fiscal year 2025. He will also provide an update on our growth strategy, including our achievements in innovation and expansion this year. Following this, Reinhard will take us through our financials. He will also present our financial guidance for the fiscal year 2026, while Andreas will comment on the new midterm guidance after 2026. As always, the presentation will be followed by a Q&A session.

Before we begin, Slide 2, I would like to remind

Recommended For You